dtpcrm: Dose Transition Pathways with Continual Reassessment Method

Features

• Design and Conduct an applied CRM and TITE-CRM with practical considerations which include stopping early for excessive toxicity and when sufficient number of subjects have been dosed at the Maximum Tolerated Dose
• Produce Dose Transition Pathways which can be used as a design tool to aid finer calibration of the CRM model or as a trial conduct tool

Author Contributions

Yap conceived and designed the modified CRM with DTP, building on the dfcrm package with added practical considerations and wrote the initial codes. Slade re-wrote the codes with support from Yap and Brock. Pan contributed to the codes, reviewed and compiled them.